

Date of Request:

P&T Committee Request Form for a Formulary/Preferred Drug List Addition, Deletion, Modification, or Comments on P&T meeting agenda items

Note: <u>ALL components of this form must be completed by the requestor for a review.</u> Use additional sheet(s) of paper if necessary. A written response will be provided to the requestor with the P&T decision after the review.

Requestor's Email Address:

Requestor's Name:	Requestor's Phone Number:
Requestor's Specialty:	Requestor's Fax Number:
Requestor's Mailing Address:	Requestor's Affiliation with Health Plan (e.g. physician, pharmacist, consumer):
Drug Requested to Review (Brand Name):	Drug Requested to Review (Generic Name):
Dosage Form:	Strength:
FDA approved Indications for use:	
Other indications for which this agent is bein this agent in the management of these indicat	•
Is there a similar drug on the Formulary?	
YesNoIf yes, please include the name	ne of the medication



Please provide rationale for addition of the drug to the formulary. Use additional sheet(s) of paper as necessary.

- 1. Is it more efficacious than other formulary drugs?
- 2. Is it more/less toxic than other formulary drugs? Are there any other special cautions or side effects?
- 3. In how many patients do you expect this drug to be used during the next six months?
- 4. What drug(s) currently used for this/these indications(s) may be deleted if this product is added to the formulary?
- 5. Is the drug more/less costly than other formulary drugs?
- 6. Is it more/less cost-effective in lowering overall health care costs?

Rationale:

Supporting Documentation: Please attach a related bibliography and copies of relevant studies from peer-reviewed literature that demonstrates superiority of this agent over others. Randomized controlled trials comparing the drug to other drugs used to treat the same disease states are preferred.

Comments on upcoming P&T Agenda Item(s): Use additional sheet(s) of paper as necessary.

- 1. P&T Meeting date and agenda item?
- 2. Comments and suggestions for committee consideration before voting occurs?



Potential Conflic	ct of Interest Disclosure: (Circle and attach comments if applicable):
	In the past 24 months, have you or your practice received research financial support from the manufacturer of this requested rug.
Yes No drug.	I have a consulting agreement with the manufacturer of this requested
	I, spouse, or a dependent have a financial interest in the this requested drug.
Requestor's Signa	ature: Date:
	Request to: PerformRx
	Request to: PerformRx PO Box 516
	Request to: PerformRx